Background

Results
Aaron Berkenwald MS4, Jacqueline Pires MS3, Pamela Ellsworth MD Nocturnal Enuresis (NE) is a common pediatric condition with an overall prevalence of 15-20% at 5 years of age, with a spontaneous resolution of about 15% per year. 2% Of children age 15 still suffer from the condition and limited treatment options exist. Behavioral therapy achieves success in nearly 3/4 of children, but many families prefer medical intervention, especially in older children. Pharmacologic therapies including Desmopressin (DDAVP) or Imipramine are effective in 40-50% of children. However Imipramine has serious safety concerns. DDAVP in combination with a fixed dose anticholinergic has been shown to be useful in individuals who fail DDAVP alone, but still fails to achieve success rates greater than 60%. We hypothesize that by titrating up the dose of Oxybutynin in combination with DDAVP in patients who fail initial monotherapy, we will achieve higher rates of success with limited additional adverse events. We will also record patient demographics, associated symptoms and co-morbidities to determine if we can predict treatment success in patient subgroups. 
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